Japanese regulator PMDA completes inspection of Lupin Mandideep facility unit, no major observations
New Delhi: Drug firm Lupin Tuesday said Japanese regulatory agency, PMDA, has concluded the inspection of Unit 2 at Mandideep facility in Madhya Pradesh with no major observations.
The inspection was conducted between May 14 and May 17, 2019, Lupin said in a statement.
The good manufacturing practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan of the company's Mandideep facility (Unit-2) has been completed, it said.
Read Also: Lupin’s Goa facility may face regulatory action, says USFDA
"The PMDA inspection closed with no critical or major observations," Lupin said.
PMDA is Japanese regulatory agency that protects public health by assuring the safety, efficacy and quality of pharmaceuticals and medical devices.
Shares of Lupin Tuesday closed at Rs 742.20 per scrip on the BSE, down 0.39 per cent from its previous close.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd